Sperm selection for assisted reproduction by prior hyaluronan binding

the HABSelect RCT

Jackson Kirkman-Brown, Sue Pavitt, Yacoub Khalaf, Sheena Lewis, Richard Hooper, Siladitya Bhattacharya, Arri Coomarasamy, Vinay Sharma, Daniel Brison, Gordon Forbes, Robert West, Allan Pacey, Kate Brian, Rachel Cutting, Virginia Bolton, David Miller (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

Background: Sperm selection for intracytoplasmic sperm injection (ICSI) has traditionally relied on standardised methods of sperm processing combined with subjective sperm selection (motility/morphology). In 2012, live birth rates (LBRs) stood at ≈24% per cycle started (32% per cycle reaching embryo transfer). Objective(s):The main clinical objective was to determine the benefits of a hyaluronan (HA)-based sperm selection process for physiological intracytoplasmic sperm injection (PICSI). A parallel, mechanistic objective evaluated sperm chromatin integrity and the potential of PICSI to compensate for poor sperm quality. Design: A Phase III, parallel-arm, blinded randomised controlled trial (RCT) of efficacy of PICSI versus ICSI alongside mechanistic evaluation. Setting: The RCT ran from February 2014 to August 2016, involving NHS (n = 14) and private (n = 2) UK hospital or satellite clinics. Mechanistic work was conducted in three university-based research laboratories and a partnering small–medium enterprise from June 2015 to December 2017. Participants: Couples undergoing an ICSI procedure using freshly ejaculated sperm with female partners aged between 18 and 43 years and male partners aged between 18 and 55 years. Intervention: Health and Care Professions Council-registered embryologists used the Medicines and Healthcare products Regulatory Agency-registered (HA-coated) PICSI™ dish (Origio, Måløv, Denmark) to select a single sperm for injection. Control couples received standard care. Main outcome measures: Clinical – the primary outcome was full-term live birth (≥ 37 weeks’ gestation). Secondary outcome measures were confirmed clinical pregnancy (CP), miscarriage following confirmation and preterm live birth (< 37 weeks’ gestation). Mechanistic – measurement models were designed for deoxyribonucleic acid (DNA) fragmentation, compaction and HA binding [HA binding score (HBS)]. Results: A total of 2772 couples were randomised and 2752 couples were included in the primary analysis (PICSI, n = 1371; and ICSI, n = 1381). Clinical – primary outcome: 379 out of 1381 (27.4% PICSI) and 346 out of 1371 (25.2% ICSI) couples who were randomised (up to 24 hours before treatment) into the trial achieved a term live birth ≥ 37 weeks’ gestation [odds ratio (OR) 1.12, 95% confidence interval (CI) 0.94 to 1.34; p = 0.18]. Subgroup analyses did not reveal differences in treatment effects for HBS, maternal age, previous miscarriage, follicle-stimulating hormone or anti-Müllerian hormone levels and paternal sperm concentrations. Secondary outcomes: CP was achieved for 487 out of 1382 (35.2% PICSI) and 491 out of 1375 (35.7%, ICSI) couples (OR 0.98, 95% CI 0.84 to 1.15; p = 0.80). Miscarriage affected 60 out of 1381 (4.3% PICSI) and 96 out of 1371 (7.0% ICSI) of couples (OR 0.61, 95% CI 0.43 to 0.84; p = 0.003). Preterm LBRs were 46 out of 1381 (3.3% PICSI) and 45 out of 1371 (3.3% ICSI) (OR 1.02, 95% CI 0.67 to 1.55; p = 0.94). Mechanistic: in the subset of samples examined, HBS correlated with sperm motility, concentration, fertilisation rate and DNA fragmentation. Sperm DNA compaction was weakly associated with clinical pregnancy rates (CPRs), but neither HBS nor DNA fragmentation was predictive of any clinical outcome. Limitations: Embryologists were not blinded and limited data were available from poorer samples and non-random sample selection in the mechanistic cohort. Prepared rather than raw semen was used for tests of DNA integrity. Conclusions: PICSI offered no clear advantage in relation to the primary outcome. PICSI led to a reduced miscarriage risk, but had no effect on CPR or preterm LBR. Future work: Re-evaluate PICSI focusing on CP and miscarriage rates and consider aspects of sperm quality that PICSI favours. Trial registration: Current Controlled Trials ISRCTN99214271.
Original languageEnglish
Number of pages110
JournalEfficacy and Mechanism Evaluation
Volume6
Issue number1
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Intracytoplasmic Sperm Injections
Hyaluronic Acid
Reproduction
Spermatozoa
Randomized Controlled Trials
Live Birth
Spontaneous Abortion
Birth Rate
Premature Birth
Pregnancy Rate
Odds Ratio
Confidence Intervals
DNA
Term Birth
Pregnancy
Sperm Motility
Satellite Hospitals
Outcome Assessment (Health Care)
Physiological Phenomena
Delivery of Health Care

Cite this

Sperm selection for assisted reproduction by prior hyaluronan binding : the HABSelect RCT. / Kirkman-Brown, Jackson; Pavitt, Sue; Khalaf, Yacoub; Lewis, Sheena; Hooper, Richard; Bhattacharya, Siladitya; Coomarasamy, Arri; Sharma, Vinay; Brison, Daniel; Forbes, Gordon; West, Robert; Pacey, Allan; Brian, Kate; Cutting, Rachel; Bolton, Virginia; Miller, David (Corresponding Author).

In: Efficacy and Mechanism Evaluation, Vol. 6, No. 1, 02.2019.

Research output: Contribution to journalArticle

Kirkman-Brown, J, Pavitt, S, Khalaf, Y, Lewis, S, Hooper, R, Bhattacharya, S, Coomarasamy, A, Sharma, V, Brison, D, Forbes, G, West, R, Pacey, A, Brian, K, Cutting, R, Bolton, V & Miller, D 2019, 'Sperm selection for assisted reproduction by prior hyaluronan binding: the HABSelect RCT', Efficacy and Mechanism Evaluation, vol. 6, no. 1. https://doi.org/10.3310/eme06010
Kirkman-Brown, Jackson ; Pavitt, Sue ; Khalaf, Yacoub ; Lewis, Sheena ; Hooper, Richard ; Bhattacharya, Siladitya ; Coomarasamy, Arri ; Sharma, Vinay ; Brison, Daniel ; Forbes, Gordon ; West, Robert ; Pacey, Allan ; Brian, Kate ; Cutting, Rachel ; Bolton, Virginia ; Miller, David. / Sperm selection for assisted reproduction by prior hyaluronan binding : the HABSelect RCT. In: Efficacy and Mechanism Evaluation. 2019 ; Vol. 6, No. 1.
@article{53659d73da5041fab1af6517ac7ce287,
title = "Sperm selection for assisted reproduction by prior hyaluronan binding: the HABSelect RCT",
abstract = "Background: Sperm selection for intracytoplasmic sperm injection (ICSI) has traditionally relied on standardised methods of sperm processing combined with subjective sperm selection (motility/morphology). In 2012, live birth rates (LBRs) stood at ≈24{\%} per cycle started (32{\%} per cycle reaching embryo transfer). Objective(s):The main clinical objective was to determine the benefits of a hyaluronan (HA)-based sperm selection process for physiological intracytoplasmic sperm injection (PICSI). A parallel, mechanistic objective evaluated sperm chromatin integrity and the potential of PICSI to compensate for poor sperm quality. Design: A Phase III, parallel-arm, blinded randomised controlled trial (RCT) of efficacy of PICSI versus ICSI alongside mechanistic evaluation. Setting: The RCT ran from February 2014 to August 2016, involving NHS (n = 14) and private (n = 2) UK hospital or satellite clinics. Mechanistic work was conducted in three university-based research laboratories and a partnering small–medium enterprise from June 2015 to December 2017. Participants: Couples undergoing an ICSI procedure using freshly ejaculated sperm with female partners aged between 18 and 43 years and male partners aged between 18 and 55 years. Intervention: Health and Care Professions Council-registered embryologists used the Medicines and Healthcare products Regulatory Agency-registered (HA-coated) PICSI™ dish (Origio, M{\aa}l{\o}v, Denmark) to select a single sperm for injection. Control couples received standard care. Main outcome measures: Clinical – the primary outcome was full-term live birth (≥ 37 weeks’ gestation). Secondary outcome measures were confirmed clinical pregnancy (CP), miscarriage following confirmation and preterm live birth (< 37 weeks’ gestation). Mechanistic – measurement models were designed for deoxyribonucleic acid (DNA) fragmentation, compaction and HA binding [HA binding score (HBS)]. Results: A total of 2772 couples were randomised and 2752 couples were included in the primary analysis (PICSI, n = 1371; and ICSI, n = 1381). Clinical – primary outcome: 379 out of 1381 (27.4{\%} PICSI) and 346 out of 1371 (25.2{\%} ICSI) couples who were randomised (up to 24 hours before treatment) into the trial achieved a term live birth ≥ 37 weeks’ gestation [odds ratio (OR) 1.12, 95{\%} confidence interval (CI) 0.94 to 1.34; p = 0.18]. Subgroup analyses did not reveal differences in treatment effects for HBS, maternal age, previous miscarriage, follicle-stimulating hormone or anti-M{\"u}llerian hormone levels and paternal sperm concentrations. Secondary outcomes: CP was achieved for 487 out of 1382 (35.2{\%} PICSI) and 491 out of 1375 (35.7{\%}, ICSI) couples (OR 0.98, 95{\%} CI 0.84 to 1.15; p = 0.80). Miscarriage affected 60 out of 1381 (4.3{\%} PICSI) and 96 out of 1371 (7.0{\%} ICSI) of couples (OR 0.61, 95{\%} CI 0.43 to 0.84; p = 0.003). Preterm LBRs were 46 out of 1381 (3.3{\%} PICSI) and 45 out of 1371 (3.3{\%} ICSI) (OR 1.02, 95{\%} CI 0.67 to 1.55; p = 0.94). Mechanistic: in the subset of samples examined, HBS correlated with sperm motility, concentration, fertilisation rate and DNA fragmentation. Sperm DNA compaction was weakly associated with clinical pregnancy rates (CPRs), but neither HBS nor DNA fragmentation was predictive of any clinical outcome. Limitations: Embryologists were not blinded and limited data were available from poorer samples and non-random sample selection in the mechanistic cohort. Prepared rather than raw semen was used for tests of DNA integrity. Conclusions: PICSI offered no clear advantage in relation to the primary outcome. PICSI led to a reduced miscarriage risk, but had no effect on CPR or preterm LBR. Future work: Re-evaluate PICSI focusing on CP and miscarriage rates and consider aspects of sperm quality that PICSI favours. Trial registration: Current Controlled Trials ISRCTN99214271.",
author = "Jackson Kirkman-Brown and Sue Pavitt and Yacoub Khalaf and Sheena Lewis and Richard Hooper and Siladitya Bhattacharya and Arri Coomarasamy and Vinay Sharma and Daniel Brison and Gordon Forbes and Robert West and Allan Pacey and Kate Brian and Rachel Cutting and Virginia Bolton and David Miller",
note = "Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. The research is also supported by the NIHR Infrastructure at Leeds and the NIHR Clinical Research Network.",
year = "2019",
month = "2",
doi = "10.3310/eme06010",
language = "English",
volume = "6",
journal = "Efficacy and Mechanism Evaluation",
issn = "2050-4373",
number = "1",

}

TY - JOUR

T1 - Sperm selection for assisted reproduction by prior hyaluronan binding

T2 - the HABSelect RCT

AU - Kirkman-Brown, Jackson

AU - Pavitt, Sue

AU - Khalaf, Yacoub

AU - Lewis, Sheena

AU - Hooper, Richard

AU - Bhattacharya, Siladitya

AU - Coomarasamy, Arri

AU - Sharma, Vinay

AU - Brison, Daniel

AU - Forbes, Gordon

AU - West, Robert

AU - Pacey, Allan

AU - Brian, Kate

AU - Cutting, Rachel

AU - Bolton, Virginia

AU - Miller, David

N1 - Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. The research is also supported by the NIHR Infrastructure at Leeds and the NIHR Clinical Research Network.

PY - 2019/2

Y1 - 2019/2

N2 - Background: Sperm selection for intracytoplasmic sperm injection (ICSI) has traditionally relied on standardised methods of sperm processing combined with subjective sperm selection (motility/morphology). In 2012, live birth rates (LBRs) stood at ≈24% per cycle started (32% per cycle reaching embryo transfer). Objective(s):The main clinical objective was to determine the benefits of a hyaluronan (HA)-based sperm selection process for physiological intracytoplasmic sperm injection (PICSI). A parallel, mechanistic objective evaluated sperm chromatin integrity and the potential of PICSI to compensate for poor sperm quality. Design: A Phase III, parallel-arm, blinded randomised controlled trial (RCT) of efficacy of PICSI versus ICSI alongside mechanistic evaluation. Setting: The RCT ran from February 2014 to August 2016, involving NHS (n = 14) and private (n = 2) UK hospital or satellite clinics. Mechanistic work was conducted in three university-based research laboratories and a partnering small–medium enterprise from June 2015 to December 2017. Participants: Couples undergoing an ICSI procedure using freshly ejaculated sperm with female partners aged between 18 and 43 years and male partners aged between 18 and 55 years. Intervention: Health and Care Professions Council-registered embryologists used the Medicines and Healthcare products Regulatory Agency-registered (HA-coated) PICSI™ dish (Origio, Måløv, Denmark) to select a single sperm for injection. Control couples received standard care. Main outcome measures: Clinical – the primary outcome was full-term live birth (≥ 37 weeks’ gestation). Secondary outcome measures were confirmed clinical pregnancy (CP), miscarriage following confirmation and preterm live birth (< 37 weeks’ gestation). Mechanistic – measurement models were designed for deoxyribonucleic acid (DNA) fragmentation, compaction and HA binding [HA binding score (HBS)]. Results: A total of 2772 couples were randomised and 2752 couples were included in the primary analysis (PICSI, n = 1371; and ICSI, n = 1381). Clinical – primary outcome: 379 out of 1381 (27.4% PICSI) and 346 out of 1371 (25.2% ICSI) couples who were randomised (up to 24 hours before treatment) into the trial achieved a term live birth ≥ 37 weeks’ gestation [odds ratio (OR) 1.12, 95% confidence interval (CI) 0.94 to 1.34; p = 0.18]. Subgroup analyses did not reveal differences in treatment effects for HBS, maternal age, previous miscarriage, follicle-stimulating hormone or anti-Müllerian hormone levels and paternal sperm concentrations. Secondary outcomes: CP was achieved for 487 out of 1382 (35.2% PICSI) and 491 out of 1375 (35.7%, ICSI) couples (OR 0.98, 95% CI 0.84 to 1.15; p = 0.80). Miscarriage affected 60 out of 1381 (4.3% PICSI) and 96 out of 1371 (7.0% ICSI) of couples (OR 0.61, 95% CI 0.43 to 0.84; p = 0.003). Preterm LBRs were 46 out of 1381 (3.3% PICSI) and 45 out of 1371 (3.3% ICSI) (OR 1.02, 95% CI 0.67 to 1.55; p = 0.94). Mechanistic: in the subset of samples examined, HBS correlated with sperm motility, concentration, fertilisation rate and DNA fragmentation. Sperm DNA compaction was weakly associated with clinical pregnancy rates (CPRs), but neither HBS nor DNA fragmentation was predictive of any clinical outcome. Limitations: Embryologists were not blinded and limited data were available from poorer samples and non-random sample selection in the mechanistic cohort. Prepared rather than raw semen was used for tests of DNA integrity. Conclusions: PICSI offered no clear advantage in relation to the primary outcome. PICSI led to a reduced miscarriage risk, but had no effect on CPR or preterm LBR. Future work: Re-evaluate PICSI focusing on CP and miscarriage rates and consider aspects of sperm quality that PICSI favours. Trial registration: Current Controlled Trials ISRCTN99214271.

AB - Background: Sperm selection for intracytoplasmic sperm injection (ICSI) has traditionally relied on standardised methods of sperm processing combined with subjective sperm selection (motility/morphology). In 2012, live birth rates (LBRs) stood at ≈24% per cycle started (32% per cycle reaching embryo transfer). Objective(s):The main clinical objective was to determine the benefits of a hyaluronan (HA)-based sperm selection process for physiological intracytoplasmic sperm injection (PICSI). A parallel, mechanistic objective evaluated sperm chromatin integrity and the potential of PICSI to compensate for poor sperm quality. Design: A Phase III, parallel-arm, blinded randomised controlled trial (RCT) of efficacy of PICSI versus ICSI alongside mechanistic evaluation. Setting: The RCT ran from February 2014 to August 2016, involving NHS (n = 14) and private (n = 2) UK hospital or satellite clinics. Mechanistic work was conducted in three university-based research laboratories and a partnering small–medium enterprise from June 2015 to December 2017. Participants: Couples undergoing an ICSI procedure using freshly ejaculated sperm with female partners aged between 18 and 43 years and male partners aged between 18 and 55 years. Intervention: Health and Care Professions Council-registered embryologists used the Medicines and Healthcare products Regulatory Agency-registered (HA-coated) PICSI™ dish (Origio, Måløv, Denmark) to select a single sperm for injection. Control couples received standard care. Main outcome measures: Clinical – the primary outcome was full-term live birth (≥ 37 weeks’ gestation). Secondary outcome measures were confirmed clinical pregnancy (CP), miscarriage following confirmation and preterm live birth (< 37 weeks’ gestation). Mechanistic – measurement models were designed for deoxyribonucleic acid (DNA) fragmentation, compaction and HA binding [HA binding score (HBS)]. Results: A total of 2772 couples were randomised and 2752 couples were included in the primary analysis (PICSI, n = 1371; and ICSI, n = 1381). Clinical – primary outcome: 379 out of 1381 (27.4% PICSI) and 346 out of 1371 (25.2% ICSI) couples who were randomised (up to 24 hours before treatment) into the trial achieved a term live birth ≥ 37 weeks’ gestation [odds ratio (OR) 1.12, 95% confidence interval (CI) 0.94 to 1.34; p = 0.18]. Subgroup analyses did not reveal differences in treatment effects for HBS, maternal age, previous miscarriage, follicle-stimulating hormone or anti-Müllerian hormone levels and paternal sperm concentrations. Secondary outcomes: CP was achieved for 487 out of 1382 (35.2% PICSI) and 491 out of 1375 (35.7%, ICSI) couples (OR 0.98, 95% CI 0.84 to 1.15; p = 0.80). Miscarriage affected 60 out of 1381 (4.3% PICSI) and 96 out of 1371 (7.0% ICSI) of couples (OR 0.61, 95% CI 0.43 to 0.84; p = 0.003). Preterm LBRs were 46 out of 1381 (3.3% PICSI) and 45 out of 1371 (3.3% ICSI) (OR 1.02, 95% CI 0.67 to 1.55; p = 0.94). Mechanistic: in the subset of samples examined, HBS correlated with sperm motility, concentration, fertilisation rate and DNA fragmentation. Sperm DNA compaction was weakly associated with clinical pregnancy rates (CPRs), but neither HBS nor DNA fragmentation was predictive of any clinical outcome. Limitations: Embryologists were not blinded and limited data were available from poorer samples and non-random sample selection in the mechanistic cohort. Prepared rather than raw semen was used for tests of DNA integrity. Conclusions: PICSI offered no clear advantage in relation to the primary outcome. PICSI led to a reduced miscarriage risk, but had no effect on CPR or preterm LBR. Future work: Re-evaluate PICSI focusing on CP and miscarriage rates and consider aspects of sperm quality that PICSI favours. Trial registration: Current Controlled Trials ISRCTN99214271.

UR - http://www.mendeley.com/research/sperm-selection-assisted-reproduction-prior-hyaluronan-binding-habselect-rct

U2 - 10.3310/eme06010

DO - 10.3310/eme06010

M3 - Article

VL - 6

JO - Efficacy and Mechanism Evaluation

JF - Efficacy and Mechanism Evaluation

SN - 2050-4373

IS - 1

ER -